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Disease modifying anti-
rheumatic drugs (DMARDs)Abstract Introduction: Clinical remission is a realistic goal in rheumatoid arthritis (RA) patients.
Doppler signals-synovitis may also be considered predictive of clinical flare-ups in RA. Objective:
The aim of this study was to detect subclinical synovitis and erosions by musculoskeletal ultrasound
(MSUS) in RA patients with clinical remission and free from physical synovitis.
Materials and methods: 41 RA patients were studied who achieved clinical remission for at least
6 months proved by clinical disease activity index (CDAI) and DAS28 without tender neither swol-
len joints. MSUS of 22 joint done for each patient, the data of gray scale (GSUS) and color Doppler
ultrasound (CDUS) graded on a semi-quantitative scale from 0 to 3.
Results: The percentage of RA patients with subclinical synovitis present in at least one joint with
CDUSP 1, and CDUSP 2 were 70.7% and 29.2% respectively. The results of CDUS were signif-
icantly lower with biologic agents compared to patients on conventional disease modifying anti-
rheumatic drugs (DMARDs) alone (p= 0.01). There was a strong association between CDUS syn-
ovitis and MSUS bone erosions (p< 0.00001).
Conclusion: Doppler detected subclinical synovitis could be considered a reliable marker to
appraise disease activity in RA patients compared to DAS28 and CDAI, in associated joint destruc-
tion secondary to erosions.
 2016 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).1. Introduction
Rheumatoid arthritis (RA) treatment has improved dramati-
cally over the past decades with the early and intensive use
986 T. Elkhouly et al.of disease modifying anti-rheumatic drug (DMARDs) strate-
gies (1) and the introduction of biological agents (2). If inflam-
mation is not treated effectively earlier structural damage in
RA will occur. Targeted treatment reduces inflammation;
therefore, the start of an early, tailored treatment with conven-
tional and/or biological (DMARDs), corticosteroids, coupled
with a ‘treat to target’ (T2T) strategy aiming remission, repre-
sents the ultimate goal (3). Disease activity assessment in RA is
important for treatment efficiency and predicting the disease
outcome. Thus, a sensitive imaging method coupled with thor-
ough clinical examination is required to monitor the disease
progress. Clinical remission is considered a realistic therapeutic
goal in RA patients (4).
New classification criteria (5) and new remission criteria (6)
have been published. It is suggested that imaging techniques
such as ultrasonography (US) could be used for additional
joints assessment as noninvasive technique without radiation
exposure (5).
In particular, gray-scale ultrasonography to detect synovitis
and Doppler signals at multiple joint levels could be modified
after effective therapy (7). Doppler signals serve as a useful
adjunct to gray-scale imaging; thus, it is more sensitive for
the detection of early disease and furthermore, it could be
more accurate to differentiate between chronic and acute dis-
ease of the thickened synovium (8).
Residual Doppler signals-synovitis is also predictive of clin-
ical flare-ups in RA (9). RA patients with clinical remission
who have residual Doppler signals synovitis do not achieve
true remission theoretically; they are at risk for subsequent
structural damage and flare. However, the subjects in the
above studies had slightly tender or swollen joints upon phys-
ical examination in spite of the fact that they achieved clinical
remission (9–14).
The aim of this study was to detect subclinical synovitis and
erosions by gray scale ultrasound (GSUS) and Color Doppler
ultrasound (CDUS) in RA patients with clinical remission and
free from physical synovitis.
2. Materials and methods
2.1. Patients
Forty-one patients who had been diagnosed as RA according
to the 2010 ACR/EULAR criteria (15) were consecutively
recruited from Al Hada Armed Forces Hospital, Rheumatol-
ogy Clinic. We included in this study all of the patients
achieved clinical remission [disease activity score
(DAS28 6 2.6) and clinical disease activity index
(CDAI 6 2.8)] for at least 6 months at the time of MSUS
examination. Furthermore, all the patients did not have any
tender or swollen joints among 28 sites at the time of MSUS
examination (see Figs. 1–3).
Exclusion criteria included any patient who did not fulfill
the ACR/EULAR criteria, any patient with DAS28 > 2.6 or
CDAI > 2.8 score with in the previous 6 months of MSUS
examination, and any patients with tender or swollen joints
among 28 sites at the time of MSUS examination.
Patients gave their informed consent and The Commission
Hospital Ethics and Research Committee approved the
study.2.2. Clinical and laboratory assessment
Clinical evaluation was performed by two Rheumatologists
who were blinded to the MSUS findings. Disease activity
was evaluated by the DAS28-ESR and CDAI (16). The
rheumatoid factor (RF), the anti-cyclic citrullinated peptide
antibodies [(anti-CCP Abs) done by the chemiluminescence
microparticle immunoassay (CMIA)], ESR (by Westergren
method), C-reactive protein ((CRP) using the enzyme linked
immunosorbent assay (ELISA)] technique and clinical disease
activity were evaluated on the day of the MSUS examination.
2.3. MSUS assessment
Each patient underwent MSUS assessment evaluation by an
expert radiologist who was blinded to the clinical findings. A
systematic multiplanar GSUS and CDUS examination of 22
joints was performed with the same scanner (Philips CX50)
using a multifrequency linear transducer (5–12 MHz) and Phi-
lips L15-7Io Compact Linear Array (Hockey Stick) 23MM
Transducer (15–7 MHz). The US score included the following
22 joints: bilateral wrists and finger joints including the first to
fifth MCP joints, the first IP joint and the second to fifth PIP
joints. All joint regions were examined in a standardized man-
ner according to the EULAR and JCR guidelines (17).
Gray scale (GSUS) synovitis was diagnosed by presence of
joint effusion (JE) and/or synovial hypertrophy (SH). The
presence of JE/SH was identified in each joint as abnormal
anechoic/isoechoic intra-articular material according to the
Outcome Measures in RA Clinical Trials (OMERACT) defini-
tions (18). Each joint was scored for both GSUS and CDUS
on a semiquantitative scale from 0 to 3 (19). Synovial hypertro-
phy in GSUS is as follows:
Grade 0 = absence which means no synovial thickening.
Grade 1 = mild, which means minimal synovial thickening
obliterating the angle between the periarticular bones with-
out bulging over the line linking the tops of the bones.
Grade 2 = moderate, which means synovial thickening bul-
ging over the line linking the tops of the periarticular bones
but without extension to at least one bone diaphysis.
Grade 3 = marked, synovial thickening bulging over the
line linking the tops of the periarticular bones and with
extension to at least one of the bone diaphysis.
Considering that minimal effusion can be detectable even in
healthy subjects, in particular, the maximum distance from the
bony surface and the capsule was 2 mm for MCP, PIP, wrists,
and 4 mm for knee according to Naredo et al. (20) Doppler
signal was graded on a semi-quantitative scale from 0 to 3:
0 = absence or minimal flow.
1 = mild: single vessel signal.
2 = moderate: confluent vessels.
3 = marked: vessel signals in >50% of the joint area.
Doppler frequency was set higher for the study of small
joints and superficial tissues, and lower for deep structures.
Color gain was set just below the level that causes the appear-
ance of noise artifacts. In the latest generation US systems, the
difference between CDUS and PDUS is not so evident because
Fig. 1 GSUS longitudinal (A) and transverse (B) scan of the wrist in RA patient shows hypoechoic fluid encasing the extensor tendon
denoting tenosynovitis with synovial hypertrophy (arrow) and effusion of the wrist joint.
Fig. 2 GSUS longitudinal (A) and transverse (B) scan of the MCP joint in RA patient shows irregular cortical outline and discontinuity
denoting erosions (arrows) not detected in plain radiograph.
Fig. 3 CDUS longitudinal scan of the wrist joint in RA patient
shows hypo and isoechoic soft tissue signal of synovial hypertro-
phy (arrow) with mild effusion and color Doppler signal grade 2
suggestive of acute/active synovitis.
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tion also on the flow direction (20).
The presence of tenosynovitis was defined as abnormal
hypoechoic or anechoic appearance of the tendon with or
without fluid inside the tendon sheath with positive Color
Doppler signals in two perpendicular planes (21). An erosionis defined by a cortical break seen in two perpendicular planes
(19).
2.4. Statistical analysis
Data were collected, tabulated, and analyzed using the scien-
tific package of social statistics version 22. The mean, standard
deviation and statistical significance were calculated by Stu-
dent’s ‘‘t’’ test for paired data. The Mann–Whitney test using
the standard error of the mean to calculate z was used for com-
parison of CDUS and GSUS parameters and its relation to
medications. Fisher’s test and the Chi square test were used
to compare the probability of variables. A value of p< 0.05
was considered statistically significant. Correlation coefficient
‘‘r’’ for the relationship of different variables was calculated
using Pearson’s coefficient for quantitative data and Spear-
man’s correlation for qualitative non-parametric data.
3. Results
Forty-one RA patients achieved definite clinical remission,
with a mean age, disease duration, duration of remission,
ESR, CRP: 50.4 ± 13.8 years, 9.5 ± 7.6 years, 9.6
± 6.7 months, 25.8 ± 5.3 mm/1st hour and 1.8 ± 0.74 mg/L
respectively. Twenty patients (48.7%) were treated with
conventional cDMARDs (12 patients with MTX/HCQ
Table 2 Comparisons between treatment regimens regarding
GSUS and CDUS ultrasound findings.
Treatment Number z P value
GSUS cDMARDs bDMARDs total 20 2.895 0.07
21
41
CDUS cDMARDs bDMARDs
total
20 2.757 0.01
21
41
988 T. Elkhouly et al.combination, 5 patients with SSZ/HCQ/MTX combination
and 3 patients on leflunomide/HCQ combination). Also there
were twenty -one patients (51.3%) on combination of
cDMARDs and biologic DMARDs (bDMARDs) (7 patients
on abatacept, 7 patients on etanercept, 5 patients on adali-
mumab, one patient on rituximab and one patient on tocilizu-
mab). All the patients achieved Boolean remission. In
addition, none of the patients exhibited tender or swollen
joints on their established medications.
The number (%) of RA patients achieved clinical remission,
with subclinical synovitis present in at least one joint in
GSUSP 1, and GSUSP 2 was 75.6% and 31.7% respec-
tively [GS grade 1, was 18 (43.9%); GS grade 2, was 10
(24.4%); GS grade 3, was 3 (7.3%)]. However CDUSP 1,
and CDUSP 2 were 70.7% and 29.2% respectively [CD grade
1, was 17 (41.5%); CD grade 2, was 9 (21.9%) and CD grade 3,
was 2 (7.3%)].
The clinical characteristics were compared between patients
with subclinical CDUS synovitis and patients without CDUS
synovitis, and between patients with CDUS grade P2 (0/1)
and patients with CDUS gradeP2 (2/3) (Table 1). There were
no statistical significance differences between the studied
groups regarding age, sex disease duration, duration of remis-
sion, RF, CCP Abs, and CRP, while statistically significant
differences were found regarding tenosynovitis (p= 0.02)
and GSUS (p= 0.03) in CDUS +ve and ve subgroups.
Also, statistically significant differences regarding ESR
(p= 0.004), bony erosions (p= 0.001) and GS (p= 0.004)
were found to be lower in patients with CDUS 0/1 rather than
patients with CDUS 2/3.
The use of cDMARDs and disease activity was not differ-
ent among the groups (Table 2). However, the results of
CDUS were significantly lower regarding the use of biologic
agents compared to patients on cDMARDs only (p= 0.01).
We confirmed an association between CDUS synovitis with
MSUS bone erosions during scanning in 902 joints from 41
patients. As shown in Table 3, there was a strong association
between CDUS synovitis and MSUS bone erosion
(p< 0.00001).
4. Discussion
Many clinically inactive RA patients have evidence of persis-
tent synovitis on magnetic resonance imaging (MRI) or mus-Table 1 Clinical and demographic characters of the studied patien
CDUS VE (16) CDUS +
Age, mean/SD 49.7 ± 13.8 50.6 ± 1
Sex, female/male 13/3 18/7
Disease duration (months), mean/SD 13.25 ± 8.89 8.56 ± 5
Duration of remission (years), mean/SD 14.5 ± 8.91 10.84 ±
+ve CCP (n), % 6 (37.5%) 17 (68%
+ve RF (n), % 12 (75%) 17 (68%
CRP mean/SD, mg/L 1.6 ± 0.7 2 ± 0.77
ESR mean/SD, mm/1st hour 19 ± 8.2 14.88 ±
DAS 28, mean/SD 1.5 ± 0.3 1.75 ± 0
CDAI median (range) 0.7 (0–2) 0.6 (0–2)
Tenosynovitis (n), % 1 (6.3%) 6 (24%)
Erosions (n), % 1 (6.3%) 14 (56%
GSUS (n), % 8 (50%) 23 (92%culoskeletal ultrasound (MSUS) scanning (22). Joint
inflammation determined by MSUS or MRI not by physical
examination is defined as subclinical synovitis (9,10). The Dop-
pler US subclinical synovitis, has been proven by several stud-
ies showing that its presence is considered predictive for
radiographic progression in the future (9,23).
In our study, none of the RA patients had tender or swollen
joints upon physical examination and achieved clinical remis-
sions with subclinical synovitis present in at least one joint in
GSUSP 1, and GSUSP 2 were 75.6% and 31.7% respec-
tively, while in CDUSP 1, and CDUSP 2 were 70.7% and
29.2% respectively.
Wakefield et al. study published regarding this issue in the
Annals 2004, highlighted the relative insensitivity of routine
clinical examination in identifying inflamed joints, and sug-
gested that subclinical synovitis may be common (24). This
hypothesis further analyzed in Harman et al. study 2015 and
showed that persistence of the PDUS signal led to radio-
graphic deterioration (25).
The positivity rate of anti-CCP Antibodies was 29% in
Scire et al. (9), and RF 41% in Sakellariou et al. (26); however,
the present cases were 68% regarding RF and 53% regarding
anti-CCP Antibodies which were much higher than the
previous ones, thus may have influenced our results. In
addition, regarding therapies, the absence of CDUS synovitis
was likely to be associated with bDMARDs which support
the evidence of biologic agents is superior to cDMARDs in
terms of radiologic progression (27).
So patients who do not exhibit active disease can be consid-
ered for alternative therapeutic approaches that are more likely
to be beneficial. The idea of routine MSUS examination into
the assessment of RA disease activity will require carefults.
VE (25) P-value CDUS 0/1 (27) CDUS 2/3 (14) P-value
4.07 0.877 49.1 ± 13.8 55 ± 13.5 0.331
0.65 20/7 11/3 0.4
.7 0.09 9.3 ± 6.3 11.42 ± 8.8 0.535
11.82 0.423 12.7 ± 5.2 9.42 ± 3.7 0.486
) 0.48 15 (55.5%) 8 (57.1%) 0.38
) 0.55 19 (70.4%) 10 (71.4%) 0.3
0.43 1.8 ± 0.8 2.3 ± 0.74 0.49
7.4 0.241 13.8 ± 6.2 19.6 ± 11.7 0.004
.56 0.189 1.67 ± 0.57 1.62 ± 0.3 0.8
0.5 0.6 (0–2) 0.1 (0–2) 0.25
0.02 2 (7.4%) 5 (35.7%) 0.4
) 0.057 4 (14.8%) 11 (78.6%) 0.001
) 0.034 18 (64%) 13 (92.8%) 0.004
Table 3 Comparison between the presence of CDUS signals and its association with bony erosions.
CDUS VE CDUS +VE P-value Sensitivity Specificity VE LR +VE LR
Bone erosion VE 806 81 <0.00001** 95% 99.88% 118.92 0.85
Bone erosion +VE 1 14
Fisher’s test.
** Highly statistical significance.
Validity of Doppler subclinical synovitis 989consideration. However, till now there is no universal agree-
ment upon a limited joint set or MSUS definition of active dis-
ease. The joint set used in our study was similar to a number of
proposed sets that are currently being implemented in Shin
et al. 2014 study (28).
Since the existence of Doppler signals was considered a risk
factor for further radiologic progression in RA (23), the sup-
pression of Doppler signals by biologic agents may explain
the preferential protective effect. Also, we found that the per-
centage of patients with US bone erosion was higher in those
with subclinical CDUS synovitis than in those without CDUS
synovitis. Furthermore, the frequency of the joints with US
bone erosions was much higher in the joints with CDUS sig-
nals as compared with the joints without CDUS signals. These
data support the coexistence of CDUS signals with US bone
erosions in RA even after they have achieved definitive clinical
remission (28).
It would be reasonable for patients with Doppler synovitis
to show a high GSUS score, which was also significant in our
study. In RA patients, Doppler signals with GSUS thickening
of synovial tissues reflect synovial cell hyperplasia with neovas-
cularization (29).
This supports the hypothesis that clinical assessment alone
is inaccurate to guide therapeutic decisions and that radiologic
remission may be a more appropriate treat to target parameter
for optimizing outcomes (28). However, other studies sug-
gested that radiographic progression in patients with DAS28
remission is restricted to those patients who continue to have
clinical evidence of joint inflammation. Patients with sustained
DAS28 remission have very little disease progression (30).
Lane et al. (25) suggested that the challenge lies not only with
the clinical assessment but also with the durability and extent
of clinical response. The current study supports the hypothesis
of routine MSUS examination within clinical disease assess-
ment in RA facilitates more accurate measurement of disease
activity and consequently management decisions. It is well
known that tapering biologics or non-biologics DMARDs
after clinical remission in RA patients who fulfilled remission
criteria is associated with percentage of relapse rates (31). Nar-
edo et al. (2015) results suggested that Doppler-detected syn-
ovitis could predict treatment tapering failure in RA patients
in sustained clinical remission (32). So delaying tapering of
medications in those with subclinical CDUS synovitis could
stop possible future relapse and improve the clinical outcome.
As stated by the Targeted Ultrasound Initiative Group (33),
to achieve imaging remission the suppression of residual Dop-
pler synovitis is suggested as a target. Thus, our present data
may emphasize the importance of subclinical Doppler synovi-
tis and suggest that it may be a promising marker to achieve
complete remission in RA patients.
To conclude, Doppler subclinical synovitis persistence in
RA patients achieving clinical remission free from physicalsynovitis is to be considered as reliable activity marker com-
pared to DAS28 and CDAI especially in associated joint
destruction due to erosions. However larger-scale longitudinal
randomized controlled trials are needed to confirm our find-
ings. Overall, the message from this work is to question quies-
cence of RA and possible value of treating disease in clinical
remission but CDUS positive synovitis. Considerably larger,
more powerful studies will be needed to make the case for rou-
tine US follow-up of RA and possibility of treatment escala-
tion or tapering for clinically quiescent disease.
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